Show simple item record

Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease

dc.contributor.authorKotagal, Vikasen_US
dc.contributor.authorAlbin, Roger L.en_US
dc.contributor.authorMüller, Martijn L. T. M.en_US
dc.contributor.authorKoeppe, Robert A.en_US
dc.contributor.authorChervin, Ronald D.en_US
dc.contributor.authorFrey, Kirk A.en_US
dc.contributor.authorBohnen, Nicolaas I.en_US
dc.date.accessioned2012-05-21T15:48:27Z
dc.date.available2013-06-11T19:15:52Zen_US
dc.date.issued2012-04en_US
dc.identifier.citationKotagal, Vikas; Albin, Roger L.; Müller, Martijn L. T. M. ; Koeppe, Robert A.; Chervin, Ronald D.; Frey, Kirk A.; Bohnen, Nicolaas I. (2012). "Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease." Annals of Neurology 71(4): 560-568. <http://hdl.handle.net/2027.42/91165>en_US
dc.identifier.issn0364-5134en_US
dc.identifier.issn1531-8249en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/91165
dc.description.abstractObjective: Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely understood. RBD and cholinergic system degeneration are identified independently as risk factors for cognitive impairment in PD. We aimed to assess the association between cholinergic denervation and symptoms of RBD in PD patients without dementia. Methods: Eighty subjects with PD without dementia (age, 64.6 ± 7.0 years; range, 50–82 years; 60 males, 20 females; mean Montreal Cognitive Assessment Test [MoCA] score, 26.2 ± 2.1; range 21–30) underwent clinical assessment, neuropsychological testing, and [ 11 C]methylpiperidyl propionate acetylcholinesterase and [ 11 C]dihydrotetrabenazine (DTBZ) vesicular monoamine transporter type 2 positron emission tomography (PET) imaging. 11 C3‐Amino‐4‐(2‐dimethylaminomethyl‐phenylsulfaryl)‐benzonitrile (DASB) serotonin transporter PET imaging was performed in a subset of 35 subjects. The presence of RBD symptoms was determined using the Mayo Sleep Questionnaire. Results: Twenty‐seven of 80 subjects (33.8%) indicated a history of RBD symptoms. Subjects with and without RBD symptoms showed no significant differences in age, motor disease duration, MoCA, Unified Parkinson Disease Rating Scale motor scores, or striatal DTBZ binding. Subjects with RBD symptoms, in comparison to those without, exhibited decreased neocortical, limbic cortical, and thalamic cholinergic innervation (0.0213 ± 0.0018 vs 0.0236 ± 0.0022, t = 4.55, p < 0.0001; 0.0388 ± 0.0029 vs 0.0423 ± 0.0058, t = 2.85, p = 0.0056; 0.0388 ± 0.0025 vs 0.0427 ± 0.0042, t = 4.49, p < 0.0001, respectively). Brainstem and striatal DASB binding showed no significant differences between groups. Interpretation: The presence of RBD symptoms in PD is associated with relative neocortical, limbic cortical, and thalamic cholinergic denervation although not with differential serotoninergic or nigrostriatal dopaminergic denervation. The presence of RBD symptoms may signal cholinergic system degeneration. ANN NEUROL 2012;en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.titleSymptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson diseaseen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Neurology, University of Michigan, and Clinic Center, Veterans Administration Ann Arbor Health Systemen_US
dc.contributor.affiliationumDepartment of Neurology, University of Michigan Medical School, 2301 Commonwealth Boulevard, Room 1013, Ann Arbor, MI 48105‐2945en_US
dc.contributor.affiliationumDepartment of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherNeurology Service and Geriatric Research, Education, and Clinic Center, Veterans Administration Ann Arbor Health Systemen_US
dc.identifier.pmid22522445en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/91165/1/22691_ftp.pdf
dc.identifier.doi10.1002/ana.22691en_US
dc.identifier.sourceAnnals of Neurologyen_US
dc.identifier.citedreferenceGinovart N, Wilson A, Meyer J, et al. Positron emission tomography quantification of [(11)C]‐DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001; 21: 1342 – 1353.en_US
dc.identifier.citedreferenceThompson CJ, Kecani S, Boelen S. Evaluation of a neck‐shield for use during neurological studies with a whole‐body PET scanner. IEEE Trans Nucl Sci 2001; 48: 1512 – 1517.en_US
dc.identifier.citedreferenceJewett DM, Kilbourn MR, Lee LC. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997; 24: 197 – 199.en_US
dc.identifier.citedreferenceInnis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533 – 1539.en_US
dc.identifier.citedreferenceSnyder SE, Tluczek L, Jewett DM, et al. Synthesis of 1‐[11C]methylpiperidin‐4‐yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998; 25: 751 – 754.en_US
dc.identifier.citedreferenceLogan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834 – 840.en_US
dc.identifier.citedreferenceKoeppe RA, Frey KA, Kume A, et al. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)‐alpha‐[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997; 17: 919 – 931.en_US
dc.identifier.citedreferenceKoeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 1999; 19: 1376 – 1384.en_US
dc.identifier.citedreferenceKoeppe RA, Frey KA, Snyder SE, et al. Kinetic modeling of N‐[11C]methylpiperidin‐4‐yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab 1999; 19: 1150 – 1163.en_US
dc.identifier.citedreferencePostuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 2010; 81: 1008 – 1013.en_US
dc.identifier.citedreferenceGilman S, Koeppe R, Chervin R, et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 2003; 8: 29 – 34.en_US
dc.identifier.citedreferenceAlbin R, Koeppe R, Chervin R. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000; 55: 1410 – 1412.en_US
dc.identifier.citedreferenceKim YK, Yoon IY, Kim JM, et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur J Neurol 2010; 17: 487 – 492.en_US
dc.identifier.citedreferenceBoeve B, Silber M, Saper C, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007; 130 ( pt 11 ): 2770 – 2788.en_US
dc.identifier.citedreferenceRingman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000; 55: 870 – 871.en_US
dc.identifier.citedreferenceDugger BN, Murray ME, Boeve BF, et al. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to REM sleep behaviour disorder. Neuropathol Appl Neurobiol 2011 Jun 23 [Epub ahead of print].en_US
dc.identifier.citedreferenceFuller P, Sherman D, Pedersen NP, et al. Reassessment of the structural basis of the ascending arousal system. J Comp Neurol 2011; 519: 933 – 956.en_US
dc.identifier.citedreferencePostuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72: 1296 – 1300.en_US
dc.identifier.citedreferenceKuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999; 52: 691 – 699.en_US
dc.identifier.citedreferenceMesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 2004; 11: 43 – 49.en_US
dc.identifier.citedreferenceBoeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder‐neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010; 1184: 15 – 54.en_US
dc.identifier.citedreferenceGagnon JF, Bedard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002; 59: 585 – 589.en_US
dc.identifier.citedreferenceBliwise DL. Challenges in the assessment of dream enactment behavior. Sleep Med 2011; 12: 429 – 430.en_US
dc.identifier.citedreferenceBohnen NI, Frey KA. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 2007; 9: 243 – 257.en_US
dc.identifier.citedreferenceSchenck C, Bundlie S, Ettinger M, Mahowald M. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986; 9: 293 – 308.en_US
dc.identifier.citedreferenceGagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol 2009; 66: 39 – 47.en_US
dc.identifier.citedreferenceMarion MH, Qurashi M, Marshall G, Foster O. Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease? J Neurol 2008; 255: 192 – 196.en_US
dc.identifier.citedreferenceWilliams‐Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow‐up of the CamPaIGN cohort. Brain 2009; 132 ( pt 11 ): 2958 – 2969.en_US
dc.identifier.citedreferenceKehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200 – 1213.en_US
dc.identifier.citedreferenceBraak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197 – 211.en_US
dc.identifier.citedreferenceRuberg M, Rieger F, Villageois A, et al. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non‐demented patients with Parkinson's disease. Brain Res 1986; 362: 83 – 91.en_US
dc.identifier.citedreferenceBohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745 – 1748.en_US
dc.identifier.citedreferenceHilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716 – 1722.en_US
dc.identifier.citedreferenceShimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273 – 278.en_US
dc.identifier.citedreferenceFox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: on movement, mood, and madness. Mov Disord 2009; 24: 1255 – 1266.en_US
dc.identifier.citedreferenceAlbin RL, Koeppe RA, Bohnen NI, et al. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008; 28: 441 – 444.en_US
dc.identifier.citedreferenceHughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181 – 184.en_US
dc.identifier.citedreferenceHoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427 – 442.en_US
dc.identifier.citedreferenceNasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695 – 699.en_US
dc.identifier.citedreferenceGoetz CG, Fahn S, Martinez‐Martin P, et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007; 22: 41 – 47.en_US
dc.identifier.citedreferenceBoeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011; 12: 445 – 453.en_US
dc.identifier.citedreferenceAbetz L, Arbuckle R, Allen RP, et al. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical‐trial setting. Sleep Med 2006; 7: 340 – 349.en_US
dc.identifier.citedreferenceChaudhuri KR, Martinez‐Martin P. Clinical assessment of nocturnal disability in Parkinson's disease: the Parkinson's Disease Sleep Scale. Neurology 2004; 63 ( 8 suppl 3 ): S17 – S20.en_US
dc.identifier.citedreferenceGomez‐Esteban JC, Zarranz JJ, Tijero B, et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2007; 22: 1912 – 1916.en_US
dc.identifier.citedreferenceNomura T, Inoue Y, Nakashima K. Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease. J Neurol Sci 2006; 250: 39 – 44.en_US
dc.identifier.citedreferenceAarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121 – 1126.en_US
dc.identifier.citedreferenceBronnick K, Alves G, Aarsland D, et al. Verbal memory in drug‐naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology 2011; 25: 114 – 124.en_US
dc.identifier.citedreferenceDelis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test manual, adult version. 2nd ed. San Antonio, TX: Psychological Corporation, 2000.en_US
dc.identifier.citedreferenceBeatty WW, Monson N. Picture and motor sequencing in Parkinson's disease. J Geriatr Psychiatry Neurol 1990; 3: 192 – 197.en_US
dc.identifier.citedreferenceWechsler D. WAIS III technical manual. San Antonio, TX: Psychological Corporation, 1997.en_US
dc.identifier.citedreferenceDelis DC, Kaplan E, Kramer JH. Delis‐Kaplan Executive Function System (D‐KEFS): examiner's manual. San Antonio, TX: Psychological Corporation, 2001.en_US
dc.identifier.citedreferenceSchmitt FA, Farlow MR, Meng X, et al. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010; 16: 330 – 336.en_US
dc.identifier.citedreferenceStroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643 – 662.en_US
dc.identifier.citedreferenceBohnen NI, Jolles J, Twijnstra A. Modification of the Stroop Color Word Test improves differentiation between patients with mild head injury and matched controls. Clin Neuropsychol 1992; 6: 178 – 184.en_US
dc.identifier.citedreferenceWoodward TS, Bub DN, Hunter MA. Task switching deficits associated with Parkinson's disease reflect depleted attentional resources. Neuropsychologia 2002; 40: 1948 – 1955.en_US
dc.identifier.citedreferenceBohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010; 133 ( pt 6 ): 1747 – 1754.en_US
dc.identifier.citedreferenceGaltier I, Nieto A, Barroso J, Norelis Lorenzo J. Visuospatial learning impairment in Parkinson disease [in Spanish]. Psicothema 2009; 21: 21 – 26.en_US
dc.identifier.citedreferenceBenton AL, Varney NR, Hamsher K. Judgment of line orientation, form V. Iowa City, IA: University of Iowa Hospitals, 1975.en_US
dc.identifier.citedreferenceVander Borght TM, Sima AA, Kilbourn MR, et al. [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995; 68: 955 – 962.en_US
dc.identifier.citedreferenceWilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996; 47: 718 – 726.en_US
dc.identifier.citedreferenceFrey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol 2001; 86: 237 – 247.en_US
dc.identifier.citedreferenceBohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564 – 573.en_US
dc.identifier.citedreferenceShute CC, Lewis PR. Electron microscopy of cholinergic terminals and acetylcholinesterase‐containing neurones in the hippocampal formation of the rat. Z Zellforsch Mikrosk Anat 1966; 69: 334 – 343.en_US
dc.identifier.citedreferenceMeyer J. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86 – 102.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.